scholarly journals A SCIENTIFIC DRUG REVIEW ON PUNARNAVA MANDUR

2021 ◽  
Vol 9 (11) ◽  
pp. 2789-2796
Author(s):  
Chhaya Gupta ◽  
Sushma Tiwari
Keyword(s):  
Renal Failure ◽  
Platelet Count ◽  
Iron Deficiency ◽  
Clinical Research ◽  
Tablet Form ◽  
Low Platelet Count ◽  
Ancient Times ◽  
Vedic Period ◽  
Drug Review ◽  
Rbc Count

Punarnava Mandura a classical Herbo mineral formulation is available on the market either in tablet form or in Churna form and is frequently used for Anemia, Low Platelet count, Low RBC count, swelling around Joints, Generalized Swelling, Gout and other end toxins accumulation. It is also a diuretic and is useful in renal disorders. In renal failure, it is used with Mutrakrichantak Churna for getting good results. Used with it. This medicine is more commonly used in North Indian Ayurvedic practice. Clinical research involves investigating proposed med- ical treatments, assessing the relative benefits of competing therapies, and establishing optimal treatment combi- nations. It is the most fruitful line of approach for methods of diagnosis and treatment as described in Ayurvedic literature. Anaemia is the most common indicator used to screen for iron deficiency, the terms anaemia, iron defi- ciency, Pandu roga is known since Vedic period and Iron preparations for the treatment of Pandu Roga has also been well known since ancient times. Punarnava as name designates regeneration; it may help to decrease, the work of Kidneys as it has Mutral properties. Keywords: Punarnava Mandur, herbomineral, Anemia.

ASSESSMENT OF THE PLATELET COUNT IN THE PREGNANT WOMEN IN IGIMS, PATNA, BIHAR

2020 ◽  
Vol 4 (2) ◽  
Author(s):  
Tanwi Singh ◽  
Anshuman Sinha
Keyword(s):  
Platelet Count ◽  
Pregnant Women ◽  
Screening Test ◽  
Low Cost ◽  
Medical Science ◽  
Cost Effective ◽  
Platelet Indices ◽  
Increased Risk ◽  
Low Platelet Count ◽  
Severity Of The Disease

The major risk associated with low platelet count in pregnancy is the increased risk of bleeding during the childbirth or post that. There is an increased blood supply to the uterus during pregnancy and the surgical procedure requires cutting of major blood vessels. Women with thrombocytopenia are at increased risk of losing excessive blood. The risk is more in case of caesarean delivery as compared to vaginal delivery. Hence based on above findings the present study was planned for Assessment of the Platelet Count in the Pregnant Women in IGIMS, Patna, Bihar. The present study was planned in Department of Pathology, Indira Gandhi Institute of Medical Science, Patna, Bihar, India. The present study was planned from duration of January 2019 to June 2019. In the present study 200 pregnant females samples received for the platelet estimation were enrolled in the present study. Clinically platelet indices can be a useful screening test for early identification of preeclampsia and eclampsia. Also platelet indices can assess the prognosis of this disease in pregnant women and can be used as an effective prognostic marker because it correlates with severity of the disease. Platelet count is a simple, low cost, and rapid routine screening test. Hence the data generated from the present study concludes that platelet count can be used as a simple and cost effective tool to monitor the progression of preeclampsia, thereby preventing complications to develop during the gestational period. Keywords: Platelet Count, Pregnant Women, IGIMS, Patna, Bihar, etc.

Quality of Life Improvements Following Eltrombopag Treatment in Children with Chronic Immune Thrombocytopenia: Case Report

2021 ◽  
Vol 104 (4) ◽  
pp. 672-675
Keyword(s):  
Quality Of Life ◽  
Platelet Count ◽  
Receptor Agonist ◽  
Immune Thrombocytopenia ◽  
Case Series ◽  
Thrombopoietin Receptor ◽  
Thrombopoietin Receptor Agonist ◽  
Low Platelet Count ◽  
Chronic Immune Thrombocytopenia

The present case series described six chronic immune thrombocytopenia patients (cITP), with a median age of 7.7 (7.0 to 13.0) years and low platelet count at 15,500 (7,000 to 20,000)/uL. They were suffering from bleeding symptoms and side effects of treatment. After enrollment, they were treated with thrombopoietin receptor agonist (eltrombopag). Five patients responded positively, showing a median platelet count of 115,000 (39,000 to 433,000)/uL. The median dose of eltrombopag used was 1.3 (0.8 to 2.2) mg/kg/day. The quality of life (QoL) improved for all patients, with their median overall score using a Pediatric QoL questionnaire showing 25.0% improvement. Median scores also showed improvements in each sphere of life functioning as physical (30.8%), emotional (26.4%), social (16.4%), and school (21.4%). The present report demonstrated that a select group of cITP patients, with low platelet count and bleeding symptoms, benefitted from treatment with eltrombopag, as shown by increased platelet counts and improved QoL. Keywords: Chronic ITP, Thrombopoietin receptor agonist, Children

EDTA‑dependent pseudothrombocytopenia in child (clinical case report)

2021 ◽  
pp. 51-54
Author(s):  
N. A. Sokolova ◽  
M. I. Savina ◽  
O. S. Shokhina
Keyword(s):  
Platelet Count ◽  
Clinical Case ◽  
Sodium Citrate ◽  
Ethylenediaminetetraacetic Acid ◽  
Hemorrhagic Diathesis ◽  
Platelet Dysfunction ◽  
Rare Presentation ◽  
Blood Samples ◽  
Low Platelet Count ◽  
Aggregation Of Platelets

Ethylenediaminetetraacetic acid (EDTA)-dependent pseudothrombocytopenia is the phenomenon of a spurious low platelet count due to antiplatelet antibodies that cause platelet clumping in blood anticoagulated with EDTA. The aggregation of platelets in EDTA-dependent pseudothrombocytopenia is usually prevented by other anticoagulants, such as sodium citrate. EDTA-dependent pseudothrombocytopenia has never been associated with hemorrhagic diathesis or platelet dysfunction. In this article, a 2,5-year-old boy with EDTA-dependent pseudothrombocytopenia is presented because of rare presentation. We report that EDTA can induce platelet clumping, and thus spuriously low platelet counts. However, aggregation of platelets was not detected in blood samples with sodium citrate, and platelet count was normal.

My patient is thrombocytopenic! Is (s)he? Why? And what shall I do?

2013 ◽  
Vol 33 (02) ◽  
pp. 83-94 ◽  
Author(s):  
L. Alberio
Keyword(s):  
Platelet Count ◽  
Basic Knowledge ◽  
Treatment Resistant ◽  
Antithrombotic Treatment ◽  
Life Threatening ◽  
Treatment Concepts ◽  
Low Platelet Count ◽  
Thrombocytopenic Patient ◽  
Taking Care

SummarySolving the riddle of a thrombocytopenic patient is a difficult and fascinating task. The spectrum of possible aetiologies is wide, ranging from an in vitro artefact to severe treatment-resistant thrombocytopenic bleeding conditions, or even life-threatening prothrombotic states. Moreover, thrombocytopenia by itself does not protect from thrombosis and sometimes a patient with a low platelet count requires concomitant antithrombotic treatment as well. In order to identify and treat the cause and the effects of the thrombocytopenia, you have to put together several pieces of information, solving a unique jig-jaw puzzle.The present work is not a textbook article about thrombocytopenia, rather a collection of differential diagnostic thoughts, treatment concepts, and some basic knowledge, that you can retrieve when facing your next thrombocytopenic patient. Enjoy reading it, but most importantly enjoy taking care of patients with a low platelet count. I bet the present work will assist you in this challenging and rewarding clinical task.

Sign in / Sign up

Export Citation Format

Share Document